成纤维细胞生长因子受体（FGFR）正在成为参与肿瘤发生、肿瘤微环境重塑和对靶向治疗获得性耐药的关键因素。 Pemigatinib 是一种酪氨酸激酶抑制剂，选择性靶向异常的 FGFR1、FGFR2 和 FGFR3。 Pemigatinib 现已被批准用于晚期胆管癌 (CCA)，但数据表明其他肿瘤组织型也表现出 FGFR 改变，因此推测其在其他癌症环境中的潜在疗效。本系统评价基于 PRISMA 指南，旨在综合并批判性地解释有关 Pemigatinib 在癌症中使用的所有可用临床前和临床证据的结果。 2024 年 4 月，使用关键词“Pemigatinib”在 PubMed、MEDLINE 和 Scopus 数据库中进行了广泛检索。二十七项研究最终满足了所有纳入标准。 Pemigatinib 临床前和临床研究中出现的有希望的结果为 Pemigatinib 扩展到多种实体癌环境铺平了道路。版权所有 © 2024 作者。由 Elsevier B.V. 出版。保留所有权利。

Fibroblast Growth Factor Receptors (FGFRs) are emerging as key factors involved in tumorigenesis, tumor microenvironment remodeling and acquired resistance to targeted therapies. Pemigatinib is a Tyrosine-Kinase Inhibitor that selectively targets aberrant FGFR1, FGFR2 and FGFR3. Pemigatinib is now approved for advanced-stage cholangiocarcinoma (CCA) but data suggests that other tumor histotypes exhibit FGFR alterations, thus hypothesizing its potential efficacy in other cancer settings. The present systematic review, based on PRISMA guidelines, aims to synthetize and critically interpret the results of all available preclinical and clinical evidence regarding Pemigatinib use in cancer. In April 2024, an extensive search was performed in PubMed, MEDLINE, and Scopus databases using the keyword "Pemigatinib". Twenty-seven studies finally met all inclusion criteria. The promising results emerging from Pemigatinib preclinical and clinical studies pave the way for Pemigatinib extension to multiple solid cancer settings.Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.